Market Vectors Generic Drugs ETF
What Are Biosimilars and Why Do They Benefit Generic Pharma?
BUTCHER: Going back to what you said about generics being a cheaper alternative, why are they cheaper? DUFFY: The barriers to generic markets are usually a lot lower. If we look at the United States, back in 1984 they passed the Hatch-Waxman Act and essentially what this did was allow for an expedited approval process […]
Will Generic Drugs Help Curb Healthcare Costs?
Reducing medical costs would be a high priority in all economies, and generic drugs could provide a solution.
What Are Generic Drugs and Why Are They Important?
TOM BUTCHER: What are generic drugs, and why are they important? JAMES DUFFY: Generic drugs are drugs that are comparable to their brand-name counterparts. They are comparable in terms of the dosage, effectiveness, and intended use. Generics are important because they are essentially a less-expensive alternative to their brand-name counterparts. This, of course, is expected […]
Drug Patent Expirations: $190 Billion Is Up for Grabs
According to estimates by Evaluate Pharma, a whopping $120 billion in sales was lost to patent expirations between 2009 and 2014.
Rx for Growth? Why Generic Drugs Are Gaining Traction
Rx for Growth? The trillion-dollar pharmaceutical industry has historically been dominated by a few major companies that create and supply the most important branded prescriptions on the market. Recent trends, however, point to the growth of the newest pharma blockbusters: generics. Today, approximately 60% of Americans take prescription drugs;[1. “Trends in Prescription Drug Use Among […]
The Latest on TEVA’s Oncology Business
In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).
Expert Q&A: What to Know Before Investing in Generic Pharma? (Part 2)
(continued from Part 1) 4. What is the nature of the cash flows for generics companies? Stable, driven by a constant demand for prescription drugs? Or lumpy, driven by growth from drugs coming off patent? The larger companies in this sector tend to have stable, steadier cash flows due to established lineups of approved products. […]
Why India Is So Important for Global Pharma
There are several compelling reasons for India’s rising pharma stature, including inexpensive labor, strong government support, and lower production costs.
Expert Q&A: What to Know Before Investing in Generic Pharma? (Part 1)
Market Realist analysts recently conducted a Q&A with experts from VanEck on the generic pharmaceutical industry, a space that has attracted investor interest due to upside potential from brand name drugs coming off patent, cost saving pressure in the healthcare industry, and increased worldwide demand for prescription drugs (for more on these topics, please see […]
How Demographics Are Shaping Generic Drug Growth
The generic drugs industry is likely to sustain robust growth in the coming years, and demographics are a key piece of the puzzle! In fact, demographics are shaping generic drug growth in a huge way.
Indian Pharma: Analyzing the Tailwinds for Growth
India’s strength within the pharmaceutical sector can be seen in the sheer number of pharmaceutical manufacturing plants in the country, which number approximately 10,500.
Why the Patent Cliff Is a Key Driver of Generic Drug Growth
Over the last several years, patent cliffs have led to steep revenue losses for traditional pharmaceuticals as well as created a gateway for smaller companies to come to market with generics.
What Are Pfizer’s Revenue Drivers?
Pfizer reported revenues of $13.5 billion during the second quarter—4% growth YoY compared to $12.9 million during the second quarter of 2017.
Mylan: How Its Performance Contributed to Its Valuation
In this final series of our three-part series, we’ll be looking at the last seven stocks among the top 18 cheap stocks in the S&P 500 for 2018.
Wall Street Talks: Albemarle’s Target Prices by Analyst
As of November 28, 2017, 38% of the 21 analysts covering Albemarle (ALB) stock have recommended a “buy” for the stock, and 62% have recommended a “hold.”
Wall Street’s View on Albemarle after 3Q17 Earnings Release
After Albemarle (ALB) posted its 3Q17 earnings, 20 analysts have been actively tracking the stock. About 45% of them have recommended a “buy” for the stock.
Why Generic Drugs Will Play a Key Role in the Future
Although generic drugs are the same as branded drugs in terms of the medicinal effect, their prices are extremely low compared to the branded products.